<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103555</url>
  </required_header>
  <id_info>
    <org_study_id>Treatment AOI with Bortezomib</org_study_id>
    <nct_id>NCT03103555</nct_id>
  </id_info>
  <brief_title>Treatment of Adult-Onset Immunodeficiency With Bortezomib</brief_title>
  <official_title>Treatment of Anti-Interferon-Gamma Autoantibody Associated Acquired Immunodeficiency Syndrome With Bortezomib: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is pilot study aimed to investigate the application of proteosome inhibitor, Bortezomib
      in treatment of patients with neutralizing autoantibody to IFN-γ. The investigators
      hypothesis is that bortezomib will reduce the antibody level and restore interferon-gamma
      function, resulting in clinical improvement and should be well-tolerated and safe for use in
      patients with autoantibody to IFN-γ.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients with autoantibody to IFN-γ and past or current history of proven opportunistic
      infection will receive 2 treatment cycles of bortezomib subcutaneously (4 injections of 1.3
      mg Bortezomib /m2 body surface per cycle), followed by low dose oral cyclophosphamide for 4
      month after completion treatment with bortezomib.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Titers of anti-interferon-gamma antibody after treatment with bortezomib</measure>
    <time_frame>8 weeks after first dose of bortezomib (after completion 2 cycles of bortezomib)</time_frame>
    <description>Change in titers of anti-interferon-gamma antibody after treatment with</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titers of anti-interferon-gamma antibody after treatment with bortezomib and cyclophosphamide</measure>
    <time_frame>1 year after first dose of bortezomib</time_frame>
    <description>Change in titers of anti-interferon-gamma antibody after treatment with bortezomib and cyclophosphamide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event</measure>
    <time_frame>6 months after first dose of bortezomib (after completion 4 months of cyclophosphamide)</time_frame>
    <description>Grade 4 adverse event (probably related)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease relapse</measure>
    <time_frame>6 month and 1 year after first dose of bortezomib</time_frame>
    <description>Worsening of symptoms and signs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Adult-onset Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>Bortezomib and cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two cycles of bortezomib administered subcutaneously, followed by 4 months of low dose oral cyclophosphamide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib will be subcutaneously administered in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.</description>
    <arm_group_label>Bortezomib and cyclophosphamide</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib</description>
    <arm_group_label>Bortezomib and cyclophosphamide</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21 - 60 years

          -  Positive anti-interferon-gamma autoantibody

          -  Anti-HIV negative

          -  Past or current infection with opportunistic infection (OI) such as nontuberculous
             mycobacteria, proven by culture

          -  Ability to give written consent, informed written consent

          -  Negative pregnancy test in premenopausal woman

          -  Receving antimicrobial for treatment of OI for at least one month.

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Absolute neutrophil count &lt;1.5 × 109/ L or platelet count &lt;100× 109/ L or hemoglobin
             level &lt; 8 g/dL

          -  Past history of myocardial infarction or heart failure within 6 months before
             enrollment or prolonged QT interval &gt; 450 msec at screening

          -  Renal insufficiency (GFR &lt; 30 ml/min)

          -  Abnormal liver function test (AST&gt; 3 times of UNL)

          -  Known cancer or receiving other immunosuppressive agent

          -  Known intolerability to Bortezomib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nasikarn Angkasekwinai, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Mdicine Siriraj Hospital, Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nasikarn Angkasekwinai, MD.</last_name>
    <phone>6681-8708766</phone>
    <email>nasikarn@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yupin Suputtamongkol, MD.</last_name>
    <phone>662-4197783</phone>
    <email>ysuputtamongkol@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasikarn Angkasekwinai, MD</last_name>
      <phone>66818708766</phone>
      <email>nasikarn@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yupin =Suputtamongkol, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2017</study_first_submitted>
  <study_first_submitted_qc>April 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>April 1, 2017</last_update_submitted>
  <last_update_submitted_qc>April 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-interferon gamma autoantibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Autoantibodies</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

